Thursday 16 October, 2025
Objectives: Determination of a maximum tolerated dose (MTD) still relies mainly on dose escalation studies using the algorithm-based 3+3 design although…
Read moreOral: Clinical Applications
These abstracts are expected to deal with applications of pharmacometrics whose aim is to improve individual patient treatment. They may include studies that have identified covariates that can be applied to calculate the dose, or even better, if the application was able to take patient response (concentration, biomarker) and further improve the individual dose. They can include simulation studies that explore how to improve patient treatment by dose individualization. The abstract must indicate an algorithm demonstrating how an individual patient dose is calculated.
An integrated, mechanistic model of viral eradication and its clinical applications in treatment regimens with direct-acting antivirals for chronic hepatitis C
Thursday 16 October, 2025
Background: The treatment objective in patients chronically infected with hepatitis C virus (CHC) is a sustained viral response (SVR), which…
Read moreApplication of a model based longitudinal network meta-analysis of FEV1 in COPD trials in clinical drug development
Thursday 16 October, 2025
Objectives: Efficacy benchmarking is an important decision making component in clinical drug development. Comparative effectiveness determines ranking and pricing among…
Read moreAlternative to Resampling Methods in Maximum Likelihood Estimation for NLMEMs by Borrowing from Bayesian Methodology
Thursday 16 October, 2025
Objectives: Asymptotic theory-based statistics such as confidence intervals (CI) from the covariance matrix (COV) and p-values (PVAL) from the Wald test…
Read moreOptimizing monitoring strategies of trastuzumab induced cardiotoxicity: Development and application of a population pharmacodynamic model quantifying trastuzumab induced changes in cardiac function
Thursday 16 October, 2025
Introduction Trastuzumab is a humanized monoclonal antibody that selectively binds to the extracellular domain of HER2, and improves outcome in…
Read moreOptimizing clinical diabetes drug development – what is the recipe?
Thursday 16 October, 2025
Objectives: A key challenge in diabetes drug development is to extrapolate the results from early clinical efficacy assessments (clamp studies…
Read moreSemi-mechanistic time-to-event modelling in malaria
Thursday 16 October, 2025
Objectives: Dihydroartemisinin-piperaquine is a promising antimalarial treatment of P. vivax and P. falciparum malaria. Falciparum malaria causes the majority of…
Read morePopulation and Bayesian kinetic modelling of necrosis biomarkers to assess the effect of conditioning therapies on infarct size
Thursday 16 October, 2025
Objectives: Infact size is a major predictor of subsequent cardiovascular event following ST-segment elevation myocardial infarction (STEMI). It is frequently…
Read moreA unified in vivo modeling approach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
Thursday 16 October, 2025
Objectives: We propose a unified approach to predict in vivo variation in drug exposure due to gene polymorphism or drug-drug…
Read moreAnnouncement of ACoP7
Thursday 16 October, 2025
ACoP7 is shaping up to be the most comprehensive ACoP to date! We hope that you will be able to…
Read more